
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc has demonstrated positive momentum in its clinical development, evidenced by the favorable top-line results reported in June 2023, which support the viability of its therapeutic candidates aimed at treating neurodegenerative diseases. The company's attractive current valuation indicates substantial potential upside based on a net present value (NPV) analysis, enhancing investor interest. Additionally, the progress towards achieving key milestones and the generation of positive data are expected to serve as significant catalysts for the company's stock performance moving forward.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share of $(1.28), which was significantly worse than prior estimates of $(0.69). The company faces substantial risks, including potential failures of its drug candidates to demonstrate safety and efficacy in clinical trials, challenges in gaining regulatory approvals, and difficulties in commercialization and reimbursement. Moreover, the overall environment for biotech investments, alongside balance sheet and liquidity risks, further compounds the negative outlook for Alzamend Neuro's stock.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares